Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011–2014)

• Published in: European journal of clinical microbiology & infectious diseases Vol. 36; no. 6; pp. 1013 - 1017
• Main Authors: Mendes, R. E., Sader, H. S., Smart, J. I., Castanheira, M., Flamm, R. K.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2017; Springer Nature B.V
• Subjects: Aminoglycosides - pharmacology; Anti-Bacterial Agents - pharmacology; Antibiotics; Bacteremia; Bacteremia - microbiology; Biomedical and Life Sciences; Biomedicine; Clinical isolates; Collection; Demographics; Endocarditis; Endocarditis, Bacterial - microbiology; Global Health; Gram-positive bacteria; Humans; In vitro methods and tests; Internal Medicine; Medical Microbiology; Methicillin; Microbial Sensitivity Tests; Minimum inhibitory concentration; Multidrug resistance; Original; Original Article; Public health; Staphylococcal Infections - microbiology; Staphylococcus aureus; Staphylococcus aureus - drug effects; Staphylococcus aureus - isolation & purification; Staphylococcus infections; Vancomycin; Minimum Inhibitory Concentration; Oxacillin; Broth Microdilution; Endocarditis; Daptomycin
• ISSN: 0934-9723; 1435-4373
• DOI: 10.1007/s10096-016-2865-8

The efficacy and safety of telavancin is under evaluation for the treatment of subjects with complicated Staphylococcus aureus bacteremia and S. aureus right-sided infective endocarditis. This study evaluated the telavancin activity against a global collection of S. aureus causing bloodstream infections (BSI), including endocarditis, to support the development of bacteremia/endocarditis clinical indications. This study included a total of 4191  S. aureus [1490 methicillin-resistant S. aureus (MRSA)], which were unique (one per patient) clinical isolates recovered from blood samples collected during 2011–2014 in a global network of hospitals. All isolates were deemed responsible for BSI, including endocarditis, by local guidelines. Isolates were tested for susceptibility by broth microdilution. Telavancin (MIC 50/90 , 0.03/0.06 μg/ml) inhibited all S. aureus at ≤0.12 μg/ml, the breakpoint for susceptibility. Equivalent minimum inhibitory concentration (MIC) values (MIC 50/90 , 0.03/0.06 μg/ml) were obtained for telavancin against methicillin-susceptible S. aureus (MSSA) and MRSA isolates, as well as MRSA from community and healthcare origins. Similar telavancin activities (MIC 50 , 0.03 μg/ml) were observed against MRSA subsets from North America and Europe, while isolates from the Asia-Pacific (APAC) and Latin America regions had MIC 50 values of 0.06 μg/ml. MRSA with vancomycin MIC values of 2–4 μg/ml and the multidrug resistance (MDR) subset had telavancin MIC 50 results of 0.06 μg/ml, although the MIC 100 result obtained against these subsets remained identical to those of MSSA (MIC 100 , 0.12 μg/ml, respectively). This study updates the telavancin in vitro activity, which continues to demonstrate great potency against invasive S. aureus , regardless of the susceptibility phenotype or demographic characteristics (100.0% susceptible), and supports the sought-after subsequent indications.